Skip to main content

Day: September 13, 2024

FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy

Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous (IV) Tecentriq1,2 New subcutaneous (SC) option reduces treatment time to approximately seven minutes, compared with 30-60 minutes for IV infusion2Basel, 13 September 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq HybrezaTM (atezolizumab and hyaluronidase-tqjs), the first and only PD-(L)1 inhibitor for subcutaneous (SC), under the skin injection for patients in the United States. Tecentriq Hybreza can be injected subcutaneously over approximately seven minutes, compared with 30-60 minutes for standard intravenous (IV) infusion of Tecentriq (atezolizumab).2 It will be available for all IV indications...

Continue reading

Scatec to sell wind plant in Vietnam to SUSI Asia Energy Transition Fund

Oslo, 13 September 2024: Scatec ASA, a leading renewable energy provider, has signed an agreement to sell the 39-megawatt (MW) Dam Nai Wind farm and the associated operating company in Vietnam to Sustainable Asia Renewable Assets (“SARA”), a utility-scale renewable energy platform of the SUSI Asia Energy Transition Fund (“SAETF”). Scatec will receive an upfront consideration of USD 27 million for its 100% equity stake at completion, with potential for additional earn-out payments of up to USD 13 million that are subject to certain conditions being fulfilled prior to May 2026. “We have decided to exit Vietnam after operating the Dam Nai wind farm since the acquisition of SN Power in 2021. We are satisfied with the agreed price and the sale is in line with our strategy to optimise our portfolio and focus on markets where we see further attractive...

Continue reading

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Zenas. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $225.0 million. Zenas’ common stock is expected to begin trading on the Nasdaq Global Select Market on September 13, 2024 under the ticker symbol “ZBIO”. The offering is expected to close on September 16, 2024,...

Continue reading

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

BOSTON and LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an upsized underwritten public offering of 15,254,237 of American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $14.75 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $225 million, before deducting underwriting discounts and commissions and offering expenses payable by Centessa. All ADSs sold in the offering were offered by Centessa. The offering is expected to close on or about September 16, 2024, subject to customary closing conditions. Centessa has also granted the underwriters...

Continue reading

Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering

BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) — Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the pricing of its initial public offering of 17,500,000 shares of its common stock at a public offering price of $18.00 per share. Bicara Therapeutics’ shares are expected to begin trading on the Nasdaq Global Market on September 13, 2024 under the ticker symbol “BCAX.” The offering is expected to close on September 16, 2024, subject to the satisfaction of customary closing conditions. In addition, Bicara Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 2,625,000 shares of its common stock at the public offering price, less underwriting discounts and commissions....

Continue reading

Melcor Developments Ltd. to Acquire Melcor Real Estate Investment Trust for $4.95 per Trust Unit

EDMONTON, Alberta, Sept. 12, 2024 (GLOBE NEWSWIRE) —Melcor REIT Unitholders will receive $4.95 in cash per Trust Unit The transaction represents a premium of 61.3% to the REIT’s 30-day volume weighted average unit price on the TSX Melcor REIT’s 5.10% convertible unsecured subordinated debentures, with a maturity date of December 31, 2024, will be paid out in cash upon closing of the Transaction The REIT will have a 30-day “go-shop” period during which it is permitted to solicit superior proposals The REIT’s Board of Trustees unanimously recommends that Unitholders vote in favour of the transactionMelcor Developments Ltd. (“Melcor” or the “Company”) (TSX: MRD) and Melcor Real Estate Investment Trust (“Melcor REIT” or the “REIT”) (TSX: MR.UN) today announced that they have entered into an arrangement agreement (the “Arrangement...

Continue reading

Melcor Developments Ltd. to Acquire Melcor Real Estate Investment Trust for $4.95 per Trust Unit

EDMONTON, Alberta, Sept. 12, 2024 (GLOBE NEWSWIRE) —Melcor REIT Unitholders will receive $4.95 in cash per Trust Unit The transaction represents a premium of 61.3% to the REIT’s 30-day volume weighted average unit price on the TSX Melcor REIT’s 5.10% convertible unsecured subordinated debentures, with a maturity date of December 31, 2024, will be paid out in cash upon closing of the Transaction The REIT will have a 30-day “go-shop” period during which it is permitted to solicit superior proposals The REIT’s Board of Trustees unanimously recommends that Unitholders vote in favour of the transactionMelcor Developments Ltd. (“Melcor” or the “Company”) (TSX: MRD) and Melcor Real Estate Investment Trust (“Melcor REIT” or the “REIT”) (TSX: MR.UN) today announced that they have entered into...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.